The RxPONDER trial and its impact on best clinical practice

Share :
Published: 17 Dec 2021
Views: 3503
Prof Christos Markopoulos and Prof Giuseppe Curigliano

Prof Christos Markopoulos (National and Kapodistrian University of Athens, Athens, Greece) and Prof Giuseppe Curigliano (European Institute of Oncology, Milan, Italy) discuss the RxPONDER trial and its impact on best clinical practice.

Prof Markopoulos starts with an overview of the genetic test Oncotype DX, before the experts discuss targeting chemotherapy treatment to those patients who will derive a benefit from it.

They then discuss the results of TAILORx trial, Oxford University's Early Breast Cancer Trialists' Collaborative Group meta-analysis and the SWOG-8814 study. Prof Curigliano touches upon the method of the RxPONDER trial and they explain the results while also discussing what's new from SABCS 2021.

Prof Curigliano mentions that the RxPONDER trial shows that post-menopausal patients with 1-3+ lymph nodes and RS 0-25 can safely forego adjuvant chemotherapy without compromising invasive disease-free survival (IDFS). He notes that the distant IDFS events were shown to be 54% in pre-menopausal vs 27% in post-menopausal patients.

Prof Markopoulos and Prof Curigliano conclude by talking about how the RxPONDER trial should impact clinical practice. Prof Markopoulos mentions that these results save some post-menopausal patients from chemo and support lower chemo use with less negative effect to patients from a non-needed toxic treatment. Such sparing treatment also lowers both workload and cost to the health system.

ecancer's filming has been kindly supported by Exact Sciences through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.